DelveInsight’s “Intermediate AMD Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the intermediate AMD treatment market, historical and forecasted epidemiology, as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and intermediate AMD market forecasts through 2034, providing crucial insights for stakeholders in the intermediate AMD therapeutic area.
According to DelveInsight’s analysis, the intermediate AMD market size is anticipated to grow with a significant CAGR during the forecast period (2024-2034). In 2023, the total intermediate AMD market size across the 7MM reached approximately USD 990 million, representing substantial commercial potential in this underserved therapeutic area.
The US accounted for the largest market share across these 7MM, with ~USD 540 million. Moreover, EU4 and the UK accounted for nearly USD 320 million in 2023.
Download the Intermediate AMD Market report to understand which factors are driving the Intermediate AMD therapeutic market trends.
According to DelveInsight’s epidemiological analysis, the US accounted for the highest prevalence of intermediate AMD among the 7MM in 2023, with around 20 million cases. The age specific data reveals that AMD represents a leading cause of severe vision loss in people over age 60, with intermediate AMD serving as a critical clinical distinction due to the elevated risk of progression to more advanced AMD stages. Furthermore, it is also observed that intermediate AMD was most prevalent in the 65-84 years age group, accounting for over 45% of total cases in 2023.
The DelveInsight report categorizes the intermediate AMD patient population based on disease severity and progression risk factors. Intermediate AMD is characterized by specific features including multiple medium drusen, at least one large druse, and non-center involving geographic atrophy. This stage may manifest mild visual changes such as metamorphopsia or reduced visual acuity, making accurate diagnosis and monitoring crucial for implementing appropriate management strategies.
Discover evolving trends in the Intermediate AMD patient pool forecasts @ Intermediate AMD Epidemiology Analysis.
While no curative treatment exists for intermediate AMD currently, the therapeutic landscape is evolving with promising developments in the clinical pipeline. Currently, only two significant players, Novartis with Iptacopan and Allegro Ophthalmics with Risuteganib, are actively involved in the pipeline for intermediate AMD. Treatment emphasis currently focuses on lifestyle adjustments, dietary modifications, smoking cessation, and routine eye monitoring using tools such as the Amsler grid and comprehensive eye examinations.
According to the DelveInsight report, the intermediate AMD therapies pipeline shows promising potential despite limited current options. Novartis is developing Iptacopan (LNP023), an oral small-molecule inhibitor of complement factor B with potential immunomodulatory activity. The company is investigating iptacopan in Phase II trials for treating patients with early and intermediate age-related macular degeneration. Recently, in December 2023, the FDA approved FABHALTA (iptacopan) as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria, demonstrating the compound’s therapeutic potential.
Dive Deeper into the evolving treatment landscape @ Intermediate AMD Emerging Therapies.
Simultaneously, Allegro Ophthalmics is advancing Risuteganib (ALG-1001), a small molecule integrin inhibitor administered via intravitreal injection. The company has received FDA agreement under Special Protocol Assessment for Phase IIb/III clinical trials of risuteganib for treating intermediate, non-exudative age-related macular degeneration.
Recent developments highlight the dynamic nature of the intermediate AMD treatment landscape. The ForeseeHome AMD Monitoring Program by Notal Vision introduces innovative options for monitoring patient vision at home, addressing concerns about missing conversion from intermediate AMD to neovascular AMD. Additionally, research explores innovative approaches including photobiomodulation therapy, which stands as a prominent candidate for treating patients with intermediate AMD at earlier disease states.
Furthermore, in July 2025, Alcon announced its intent to acquire LumiThera, Inc., including its photobiomodulation (PBM) device for treating early and intermediate dry AMD. PBM is a non-invasive light therapy shown to improve vision and is already FDA-authorized, representing a significant advancement for the treatment of dry AMD. The acquisition is expected to complete in Q3 2025, aiming to expand access to this innovative therapy globally.
Discover recent advancements in the Intermediate AMD treatment landscape @ Intermediate AMD Recent Developments.
The intermediate AMD treatment market involves specialized healthcare providers including retinal specialists, ophthalmologists, and eye care professionals. Key treatment approaches include antioxidant vitamin and mineral supplementation as per the Age-related Eye Disease Study (AREDS2), which should be considered in patients with intermediate or advanced AMD. However, there is no evidence supporting supplement use for patients with less than intermediate AMD or any prophylactic value for family members without AMD signs.
Looking ahead, the intermediate AMD market faces both opportunities and challenges. Limited knowledge regarding pathophysiology, disease severity, and consequences continues to impede effective treatment development. Detecting early biomarkers signaling progression risk from intermediate AMD to vision-threatening late stages remains crucial for personalized management and timely intervention. Patients are likely to show high willingness to pay, considering the absence of approved therapies and significant unmet need, particularly given the potential to prevent progression to wet AMD with associated high treatment costs.
DelveInsight’s analysis underscores that despite current limitations, substantial opportunities exist for developing effective treatment options that can prevent disease progression and preserve functional vision. As research advances and clinical trials progress, the intermediate AMD market is positioned for significant growth and therapeutic innovation through 2034, driven by the urgent need to address this critical stage of age-related macular degeneration.
Table of Contents
1. Key Insights
2. Executive Summary of Intermediate AMD
3. Competitive Intelligence Analysis for Intermediate AMD
4. Intermediate AMD Market Overview at a Glance
5. Intermediate AMD: Disease Background and Overview
6. Intermediate AMD Patient Journey
7. Intermediate AMD Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Intermediate AMD Unmet Needs
10. Key Endpoints of Intermediate AMD Treatment
11. Intermediate AMD Marketed Products
12. Intermediate AMD Emerging Therapies
13. Intermediate AMD: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Intermediate AMD
17. KOL Views
18. Intermediate AMD Market Drivers
19. Intermediate AMD Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services